2021 DORIS definition of remission in SLE: final recommendations from an international task force

被引：233

作者：

van Vollenhoven, Ronald F. ^{[1
]}

Bertsias, George ^{[2
]}

Doria, Andrea ^{[3
]}

Isenberg, David ^{[4
]}

Morand, Eric ^{[5
]}

Petri, Michelle A. ^{[6
]}

Pons-Estel, Bernardo A. ^{[7
]}

Rahman, Anisur ^{[8
]}

Ugarte-Gil, Manuel Francisco ^{[9
]}

Voskuyl, Alexandre ^{[10
]}

Arnaud, Laurent ^{[11
,12
]}

Bruce, Ian N. ^{[13
]}

Cervera, Ricard ^{[14
]}

Costedoat-Chalumeau, Nathalie ^{[15
]}

Gordon, Caroline ^{[16
]}

Houssiau, Frederic A. ^{[17
,18
]}

Mosca, Marta ^{[19
]}

Schneider, Matthias ^{[20
,21
]}

Ward, Michael M. ^{[22
]}

Alarcon, Graciela ^{[23
]}

Aringer, Martin ^{[24
]}

Askenase, Anka ^{[25
]}

Bae, Sang-Cheol ^{[26
]}

Bootsma, Hendrika ^{[27
]}

Boumpas, Dimitrios T. ^{[28
]}

Brunner, Hermine ^{[29
]}

Clarke, Ann Elaine ^{[30
]}

Coney, Cindy ^{[31
]}

Czirjak, Laszlo ^{[32
]}

Doerner, Thomas ^{[33
]}

Faria, Raquel ^{[34
,35
]}

Fischer, Rebecca ^{[36
]}

Fritsch-Stork, Ruth ^{[37
]}

Inanc, Murat ^{[38
]}

Jacobsen, Soren ^{[39
]}

Jayne, David ^{[40
]}

Kuhn, Annegret ^{[41
]}

van Leeuw, Bernadette ^{[42
]}

Limper, Maarten ^{[43
]}

Mariette, Xavier ^{[44
]}

Navarra, Sandra ^{[45
]}

Nikpour, Mandana ^{[46
]}

Olesinska, Marzena Helena ^{[47
]}

Pons-Estel, Guillermo ^{[48
]}

Romero-Diaz, Juanita ^{[49
]}

Rubio, Blanca ^{[42
]}

Schoenfeld, Yehuda ^{[50
]}

Bonfa, Eloisa ^{[51
]}

Smolen, Josef ^{[52
]}

Teng, Y. K. Onno ^{[53
]}

机构：

[1] Amsterdam Rheumatol & Immunol Ctr, Dept Rheumatol, Amsterdam, Netherlands

[2] Univ Hosp Heraklion, Rheumatol Clin Immunol & Allergy, Iraklion, Greece

[3] Univ Padua, Div Rheumatol, Padua, Italy

[4] UCL, Ctr Rheumatol, London, England

[5] Monash Med Ctr, Melbourne, Vic, Australia

[6] Johns Hopkins Univ, Div Rheumatol, Sch Med, Baltimore, MD USA

[7] Prov Hosp Rosario, Rheumatol, Rosario, Santa Fe, Argentina

[8] UCL, Med Rheumatol, London, England

[9] Southern Sci Univ, Rheumatol, Lima, Peru

[10] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands

[11] Strasbourg Univ Hosp, Dept Rheumatol, Strasbourg, France

[12] Univ Strasbourg, Strasbourg Federat Translat Med FMTS, Strasbourg, France

[13] Univ Manchester, Manchester, Lancs, England

[14] Hosp Clin Barcelona, Barcelona, Spain

[15] Cochin Hosp, Paris, France

[16] Univ Birmingham, Rheumatol Res Grp, Birmingham, England

[17] Catholic Univ Louvain, Inst Expt & Clin Res, Pole Rheumat Pathol, Brussels, Belgium

[18] St Luc Univ Clin, Rheumatol Dept, Brussels, Belgium

[19] Univ Pisa, Pisa, Italy

[20] Heinrich Heine Univ, Policlin Rheumatol, Dusseldorf, Germany

[21] Heinrich Heine Univ, Hiller Res Ctr Rheumatol, Dusseldorf, Germany

[22] NIH, Bethesda, MD USA

[23] Univ Alabama Birmingham, Birmingham, AL USA

[24] Dresden Univ Hosp, Dresden, Germany

[25] Columbia Univ, Med Ctr, New York, NY USA

[26] Hanyang Univ, Rheumatol, Seoul Hosp, Seoul, South Korea

[27] Univ Med Ctr Groningen, Groningen, Netherlands

[28] Natl & Kapodestrian Univ Athens, Med, Athens, Greece

[29] Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH USA

[30] Univ Calgary, Calgary, AB, Canada

[31] Lupus Fdn Amer, Washington, DC USA

[32] Univ Pecs, Dept Rheumatol & Immunol, Pecs, Hungary

[33] Charite, Berlin, Germany

[34] Porto Hosp, Clin Immunol Unit, Porto, Portugal

[35] Univ Ctr, Porto, Portugal

[36] Heinrich Heine Univ, Rheumatol, Dusseldorf, Germany

[37] Hanusch Hosp, Med Dept 1, Vienna, Austria

[38] Istanbul Univ, Internal Med Rheumatol, Istanbul, Turkey

[39] Copenhagen Univ Hosp, Rheumatol, Rigshosp, Copenhagen, Denmark

[40] Univ Cambridge, Med, Sch Clin Med, Cambridge, England

[41] Univ Meunster, Meunster, Germany

[42] Lupus Europe, Brussels, Belgium

[43] UMC Utrecht, Rheumatol & Clin Immunol, Utrecht, Netherlands

[44] Paris Saclay Univ, Publ Assistance, Paris Hosp, Le Kremlin Bicetre, France

[45] Univ Santo Tomas Hosp, Rheumatol, Manila, Philippines

[46] Univ Melbourne, Med & Rheumatol, Fitzroy, Vic, Australia

[47] Inst Rheumatol, Warsaw, Poland

[48] Reg Ctr Autoimmune & Rheumat Dis GO CREAR, Rosario, Argentina

[49] Natl Inst Med Sci & Nutr Salvador Zubiran, Immunol & Rheumatol, Mexico City, DF, Mexico

[50] Sheba Med Ctr, Zabludowicz Ctr Autoimmune Dis, Tel Aviv, Israel

来源：

LUPUS SCIENCE & MEDICINE | 2021年 / 8卷 / 01期

关键词：

lupus erythematosus; systemic; outcome assessment; healthcare; therapeutics; DISEASE-ACTIVITY STATE; PROLONGED REMISSION; COHORT; LDAS;

D O I：

10.1136/lupus-2021-000538

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective To achieve consensus on a definition of remission in SLE (DORIS). Background Remission is the stated goal for both patient and caregiver, but consensus on a definition of remission has been lacking. Previously, an international task force consisting of patient representatives and medical specialists published a framework for such a definition, without reaching a final recommendation. Methods Several systematic literature reviews were performed and specific research questions examined in suitably chosen data sets. The findings were discussed, reformulated as recommendations and voted on. Results Based on data from the literature and several SLE-specific data sets, a set of recommendations was endorsed. Ultimately, the DORIS Task Force recommended a single definition of remission in SLE, based on clinical systemic lupus erythematosus disease activitiy index (SLEDAI)=0, Evaluator's Global Assessment <0.5 (0-3), prednisolone 5 mg/day or less, and stable antimalarials, immunosuppressives, and biologics. Conclusion The 2021 DORIS definition of remission in SLE is recommended for use in clinical care, education, and research including clinical trials and observational studies.

引用

页数：8

共 21 条

[1] Remission and low disease activity state (LDAS) are protective of intermediate and long-term outcomes in SLE patients. Results from LUMINA (LXXVIII), a multiethnic, multicenter US cohort [J].

Alarcon, G. S. ;

Ugarte-Gil, M. F. ;

Pons-Estel, G. ;

Vila, L. M. ;

Reveille, J. D. ;

McGwin, G. .

LUPUS, 2019, 28 (03) :423-426

[2] Time in remission and low disease activity state (LDAS) are associated with a better quality of life in patients with systemic lupus erythematosus: results from LUMINA (LXXIX), a multiethnic, multicentre US cohort [J].

Francisco Ugarte-Gil, Manuel ;

Pons-Estel, Guillermo J. ;

Vila, Luis M. ;

McGwin, Gerald ;

Alarcon, Graciela S. .

RMD OPEN, 2019, 5 (01)

[3] Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL) [J].

Francisco Ugarte-Gil, Manuel ;

Wojdyla, Daniel ;

Pons-Estel, Guillermo J. ;

Catoggio, Luis J. ;

Drenkard, Cristina ;

Sarano, Judith ;

Berbotto, Guillermo A. ;

Borba, Eduardo F. ;

Inoue Sato, Emilia ;

Tavares Brenol, Joao C. ;

Uribe, Oscar ;

Ramirez Gomez, Luis A. ;

Guibert-Toledano, Marlene ;

Massardo, Loreto ;

Cardiel, Mario H. ;

Silveira, Luis H. ;

Chacon-Diaz, Rosa ;

Alarcon, Graciela S. ;

Pons-Estel, Bernardo A. .

ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (12) :2071-2074

[4] Development of the Asia Pacific Lupus Collaboration cohort [J].

Kandane-Rathnayake, Rangi ;

Golder, Vera ;

Louthrenoo, Worawit ;

Luo, Shue-Fen ;

Wu, Yeong-Jian Jan ;

Li, Zhanguo ;

An, Yuan ;

Lateef, Aisha ;

Sockalingam, Sargunan ;

Navarra, Sandra V. ;

Zamora, Leonid ;

Hamijoyo, Laniyati ;

Katsumata, Yasuhiro ;

Harigai, Masayoshi ;

Chan, Madelynn ;

O'Neill, Sean ;

Goldblatt, Fiona ;

Hao, Yanjie ;

Zhang, Zhuoli ;

Al-Saleh, Jamal ;

Khamashta, Munther ;

Takeuchi, Tsutomu ;

Tanaka, Yoshiya ;

Bae, Sang-Cheol ;

Lau, Chak Sing ;

Hoi, Alberta ;

Nikpour, Mandana ;

Morand, Eric F. .

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2019, 22 (03) :425-433

[5] Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort [J].

Petri, Michelle ;

Magder, Laurence S. .

ARTHRITIS & RHEUMATOLOGY, 2018, 70 (11) :1790-1795

[6]

Pons-Estel G, 2020, ARTHRITIS RHEUMATOL, V72

[7] Remission and low disease activity state prevent hospitalizations in systemic lupus erythematosus patients [J].

Reategui-Sokolova, C. ;

Rodriguez-Bellido, Z. ;

Gamboa-Cardenas, R. V. ;

Medina, M. ;

Zevallos, F. ;

Pimentel-Quiroz, V. R. ;

Elera-Fitzcarrald, C. ;

Cucho-Venegas, M. ;

Pastor-Asurza, C. A. ;

Perich-Campos, R. ;

Alarcon, G. S. ;

Ugarte-Gil, M. F. .

LUPUS, 2019, 28 (11) :1344-1349

[8] Remission in systemic lupus erythematosus: testing different definitions in a large multicentre cohort [J].

Saccon, Francesca ;

Zen, Margherita ;

Gatto, Mariele ;

Margiotta, Domenico Paolo Emanuele ;

Afeltra, Antonella ;

Ceccarelli, Fulvia ;

Conti, Fabrizio ;

Bortoluzzi, Alessandra ;

Govoni, Marcello ;

Frontini, Giulia ;

Moroni, Gabriella ;

Dall'Ara, Francesca ;

Tincani, Angela ;

Signorini, Viola ;

Mosca, Marta ;

Frigo, Anna Chiara ;

Iaccarino, Luca ;

Doria, Andrea .

ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (07) :943-950

[9] The relationship between remission and health-related quality of life in a cohort of SLE patients [J].

Tsang-A-Sjoe, Michel W. P. ;

Bultink, Irene E. M. ;

Heslinga, Maaike ;

van Tuyl, Lilian H. ;

van Vollenhoven, Ronald F. ;

Voskuyl, Alexandre E. .

RHEUMATOLOGY, 2019, 58 (04) :628-635

[10] Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus [J].

Tsang-A-Sjoe, Michel W. P. ;

Bultink, Irene E. M. ;

Heslinga, Maaike ;

Voskuyl, Alexandre E. .

RHEUMATOLOGY, 2017, 56 (01) :121-128

← 1 2 3 →